Literature DB >> 2460875

Addition of a foreign oligopeptide to the major capsid protein of poliovirus.

F Colbère-Garapin1, C Christodoulou, R Crainic, A C Garapin, A Candrea.   

Abstract

Insertion mutants of type 3 poliovirus (Sabin strain) were constructed that encode additional amino acid sequences at the level of residue 100 of the capsid polypeptide VP1 within the neutralization site 1, corresponding to a loop on the capsid surface. The addition of a tri- or hexapeptide did not hamper virus viability. The antigenic pattern of insertion mutants was only modified locally: all mutants lost reactivity of neutralization site 1 with the corresponding monoclonal antibodies, while the reactivity of sites 2 and 3 was unaffected by the insertion. We have shown for one of the mutants--vFG68--that the antigenic specificity of the neutralization site 1 was replaced by a new one. Although vFG68 differs from its parental Sabin strain only by the addition of three amino acids within VP1, neutralizing antibodies specific for vFG68 were induced by the native virion as well as by the heat-denatured mutated virions. Our results demonstrate that an oligopeptide of three or six amino acids can lengthen VP1 at the level of antigenic site 1 without affecting virus multiplication and that this foreign peptide is exposed on the virion surface.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460875      PMCID: PMC282521          DOI: 10.1073/pnas.85.22.8668

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

2.  A poliovirus temperature-sensitive RNA synthesis mutant located in a noncoding region of the genome.

Authors:  P Sarnow; H D Bernstein; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

3.  Antigen chimaeras of poliovirus as potential new vaccines.

Authors:  K L Burke; G Dunn; M Ferguson; P D Minor; J W Almond
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

4.  Immune responses to H particles of poliovirus.

Authors:  Y Himuma; S Katagiri; S Aikawa
Journal:  Virology       Date:  1970-03       Impact factor: 3.616

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 6.  Rapid evolution of RNA genomes.

Authors:  J Holland; K Spindler; F Horodyski; E Grabau; S Nichol; S VandePol
Journal:  Science       Date:  1982-03-26       Impact factor: 47.728

7.  Poliovirus mutant that does not selectively inhibit host cell protein synthesis.

Authors:  H D Bernstein; N Sonenberg; D Baltimore
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

8.  Modulation of humoral response to a 12-amino-acid site on the poliovirus virion.

Authors:  J P Icenogle; P D Minor; M Ferguson; J M Hogle
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

9.  Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins.

Authors:  A J Cann; G Stanway; R Hauptmann; P D Minor; G C Schild; L D Clarke; R C Mountford; J W Almond
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

10.  Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.

Authors:  A Martin; C Wychowski; T Couderc; R Crainic; J Hogle; M Girard
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

View more
  9 in total

1.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Infectious enveloped RNA virus antigenic chimeras.

Authors:  S D London; A L Schmaljohn; J M Dalrymple; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.

Authors:  F Delpeyroux; E Van Wezel; B Blondel; R Crainic
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.

Authors:  C Christodoulou; F Colbere-Garapin; A Macadam; L F Taffs; S Marsden; P Minor; F Horaud
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus.

Authors:  M M Georgescu; M Tardy-Panit; S Guillot; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design.

Authors:  Ke Lyu; Guang-Chuan Wang; Ya-Ling He; Jian-Feng Han; Qing Ye; Cheng-Feng Qin; Rong Chen
Journal:  J Biol Chem       Date:  2014-12-09       Impact factor: 5.157

8.  A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Authors:  M Tardy-Panit; B Blondel; A Martin; F Tekaia; F Horaud; F Delpeyroux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

9.  Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera.

Authors:  T O Yeates; D H Jacobson; A Martin; C Wychowski; M Girard; D J Filman; J M Hogle
Journal:  EMBO J       Date:  1991-09       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.